Cell Line Development

Sartorius Stedim Cellca is a leading provider of cell line development and upstream process development services for large-scale protein production of biopharmaceuticals in mammalian (CHO) cells. For this purpose, Cellca has devised a unique cell line development technology platform made up of 4 key components:

Together they deliver high yielding, stable cell lines and robust, simple, fed-batch processes for the biopharmaceutical market. The Cellca CHO Expression Platform is an easily accessible, scalable and robust system that takes your product from DNA to RCB in just 4 months.

Track Record


Since inception, Sartorius Stedim Cellca has delivered over 65 CHO cell lines expressing various biologics, which have progressed to clinical trials including:

  • mAbs (IgG1, IgG4, IgG2)
  • Fc-fusion proteins
  • Fab-related products
  • Bispecific antibodies
  • Biosimilars antibodies

We have extensive experience in custom cell line development projects, including difficult to express proteins.

The Cellca CHO Expression Platform consistently delivers production processes with titres of 3 g/L or more, which is evidenced in our successful track record:

Cell Line Development

Customers First

As well as the unique technology platform, we consider our customers Cellca’s greatest asset. To achieve our purpose of providing high-producing, stable cell lines to our customers, our dedicated cross-functional project teams work meticulously on the successful realisation of each project. We believe in a continuous dialogue between the customer and project team to ensure a steady effective flow of information during all project stages. Thereby, we guarantee competent responsiveness on all levels and manage your cell line and process development program accordingly.

Our satisfied loyal customers have repeatedly recommended Cellca’s CHO cell line development and upstream process development services to their peers, enabling continuous growth of our global customer base, which currently includes about 30 big and small pharma or biotech companies from Europe, the USA, Asia, and Australia with a customer retention rate of more than 80%. Industry references available on request.

Contact our experts to discuss our cell line development services today.

Contact us


Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

* you agree to receive emails with tips, news, insights and quizzes.